Abstract:Protein–protein interactions (PPIs) execute many fundamental cellular functions and have served as prime drug targets over the last two decades. Interfering intracellular PPIs with small molecules has been extremely difficult for larger or flat binding sites, as antibodies cannot cross the cell membrane to reach such target sites. In recent years, peptides smaller size and balance of conformational rigidity and flexibility have made them promising candidates for targeting challenging binding interfaces with satisfactory binding affinity and specificity. Deciphering and characterizing peptide–protein recognition mechanisms is thus central for the invention of peptide-based strategies to interfere with endogenous protein interactions, or improvement of the binding affinity and specificity of existing approaches. Importantly, a variety of computation-aided rational designs for peptide therapeutics have been developed, which aim to deliver comprehensive docking for peptide–protein interaction interfaces. Over 60 peptides have been approved and administrated globally in clinics. Despite this, advances in various docking models are only on the merge of making their contribution to peptide drug development. In this review, we provide (i) a holistic overview of peptide drug development and the fundamental technologies utilized to date, and (ii) an updated review on key developments of computational modeling of peptide–protein interactions (PepPIs) with an aim to assist experimental biologists exploit suitable docking methods to advance peptide interfering strategies against PPIs.

Main methods and tools for peptide development based on protein-protein interactions (PPIs)

A Comprehensive Review on Current Advances in Peptide Drug Development and Design

Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Targeting Protein-Protein Interaction by Small Molecules

Small molecules targeting protein‒protein interactions for cancer therapy

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Revisiting Pyrimidine-Embedded Molecular Frameworks to Probe the Unexplored Chemical Space for Protein-Protein Interactions

Protein-Protein Interactions: Interface Analysis, Binding Free Energy Calculation and Interaction Design

The Search for Peptide-Based Therapeutics Using Computational Tools

Peptide therapeutics: Targeting the undruggable space

Chemical-Protein Interactome and Its Application in Off-Target Identification

Rational design of small-molecule peptidomimetics for three pivotal protein secondary structures

Peptide docking and structure-based characterization of peptide binding: from knowledge to know-how

Design and Synthetic Strategies for Helical Peptides.

Hotspot Identification and Drug Design of Protein-Protein Interaction Modulators Using the Fragment Molecular Orbital Method

Advancements in Loop Cyclization Approaches for Enhanced Peptide Therapeutics for Targeting Protein-Protein Interactions

The power of computational proteomics platforms to decipher protein-protein interactions